Navigation Links
USPTO issues patent for "Preservation by Vaporization" technology, allowing manufacture of thermostable vaccines and other fragile biopharmaceuticals

SAN DIEGO, Nov. 16, 2016 /PRNewswire/ -- USPTO has issued a patent for a novel manufacturing process, "Preservation by Vaporization" (PBV),  invented by Dr. Victor Bronshtein, Founder, President and Chief Scientific Officer of Universal Stabilization Technologies, Inc. (UST).  This invention eliminates the need for the cold chain during storage, distribution and delivery of labile biotherapeutics. Additionally, it allows the product to be micronized into powders suitable for administration by respiratory, transdermal, oral, intravaginal, or other mucosal delivery routes, eliminating the need for both reconstitution and needle injection.

PBV can be used to preserve live attenuated vaccines (LAV) and other labile biologics, endowing them with the ambient temperature (AT) stability that is typically only possible with pharmaceuticals. Despite years of optimization, conventional freeze drying and spray drying methods have been unable to successfully thermostabilize LAVs and many other fragile biopharmaceuticals.  For this reason, most fragile biopharmaceuticals, probiotic bacteria, blood-derived products, and enzyme based diagnostics, preserved using conventional drying methods, require a well-controlled cold chain to retain potency and activity. Lack or breakdown of refrigeration for vaccines results in billions of dollars' worth of product loss during shipping and storage, and severely limits distribution to developing nations that lack infrastructure for electricity and refrigeration. Cold chain requirements are estimated to account for over 80% the cost of vaccine implementation, an expense of $200-$300 million annually for vaccination programs. Thermostable biotherapeutics, manufactured via the alternative PBV method, can alleviate these major economic and logistical burdens, which present challenges especially to developing nations.

The novel PBV process is the cornerstone of UST's VitriLife® platform for formulation and production of thermostable LAVs and biopharmaceuticals immobilized in foamed carbohydrate glasses for long-term AT stability.  PBV-enabled thermostability and alternative delivery methods are important differentiating factors for production of biobetter vaccines and other biologics.  Thermostable biobetters have the potential to take a large market share of the multibillion dollar biosimilars market. 

UST is a privately held San Diego-based biopharmaceutical R&D company focused on the formulation of long-term ambient temperature stable biopharmaceuticals.  UST offers VitriLife® research and development services for its customers as well as formulation of oral, respiratory, transdermal, sublingual, and other delivery devices for AT stable vaccines and other biopharmaceuticals.  


Universal Stabilization Technologies, Inc. 4050 Sorrento Valley Blvd. Ste. L, San Diego, CA 92121
Tel. 858-625-2896,, Website:     


To view the original version on PR Newswire, visit:

SOURCE Universal Stabilization Technologies, Inc.
Copyright©2016 PR Newswire.
All rights reserved

Related biology technology :

1. American Process, Inc. Announces Sulfite Nanocellulose Patent Allowed by USPTO
2. American Process, Inc. Announces Additional Nanocellulose Patents Granted by USPTO
3. ProteoThera, Inc. Receives USPTO Grant of Key Patent Supporting Matrix-Binding Technology Platform
4. Shire Comments on USPTO Petitions Related to LIALDA and GATTEX
5. KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511
6. Lakewood-Amedex Receives Notice Of Allowance From The United States Patent and Trademark Office (USPTO) For A New Patent Covering Its nanoRNA Gene-Silencing Technology
7. Noninvasive Imaging Technique Protects Healthy Tissues During Freezing of Cancer Lesions
8. ComplianceOnline Announces Seminar on Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions
9. Enabling Technologies Consortium (ETC) Issues Request for Information (RFI) Regarding Development of Medium Throughput Personal Reactor Platform
10. Edison Issues ADR Update on Midatech
11. Dr. Paul Janssen Award for Biomedical Research Issues 2016 Call for Nominations
Post Your Comments:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... Oct. 10, 2017 International research firm Parks Associates ... speak at the TMA 2017 Annual Meeting , October 11 in ... the residential home security market and how smart safety and security products ... Parks Associates: Smart ... "The residential security market ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
(Date:10/7/2017)... Seattle, WA (PRWEB) , ... ... ... the industry leader in Hi-C-based genomic technologies, launched its ProxiMeta™ Hi-C metagenome ... the ProxiMeta Hi-C kit and accompanying cloud-based bioinformatics software to perform Hi-C ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
Breaking Biology News(10 mins):